[1] K. Benjamin Garbutcheon-Singh, M. P. Grant, B. W. Harper, et al. Transition Metal Based Anticancer Drugs. Curr Top Med Chem. 11 (2011) 521-542.
[2] C. M. Che, F. M. Siu, Metal complexes in medicine with a focus on enzyme inhibition. Curr Opin Chem Biol. 14 (2010) 255-261.
[3] R. W. Y. Sun, D. L. Ma, E. L. M. Wong, C. M. Che, Some uses of transition metal complexes as anti-cancer and anti-
HIV agents. Dalt Trans. 43 (2007) 4884-4892.
[4] T. W. Hambley, Developing new metal-based therapeutics: Challenges and opportunities. Dalt Trans. 43 (2007) 4929-4937.
[5] B. Lu, D. Ennis, R. Lai, et al. Enhanced Sensitivity of
Insulin-resistant Adipocytes to Vanadate is Associated with Oxidative Stress and Decreased Reduction of Vanadate (+5) to Vanadyl (+4). J Biol Chem. 276 276 (2001) 35589-35598.
[6] S. Trudel, M. R. Paquet, S. Grinstein, Mechanism of vanadate-induced activation of tyrosine phosphorylation and of the respiratory burst in HL60 cells. Role of reduced oxygen metabolites. Biochem J. 276 (1991) 611-619.
[7] H. Sakurai, M. Nakai, T. Miki, K. Tsuchiya, J. Takada, R. Matsushita, DNA cleavage by hydroxyl radicals generated in a vanadyl ion-hydrogen peroxide system. Biochem Biophys Res Commun. 189 (1992) 1090-1095.
[8] K. H. Thompson, C. Orvig, Coordination chemistry of vanadium in metallopharmaceutical candidate compounds. Coord Chem Rev. 219 (2001) 1033-1053.
[9] O. J. D’Cruz, Y. Dong, F. M. Uckun, Potent dual anti-HIV and spermicidal activities of novel oxovanadium(V) complexes with thiourea non-nucleoside inhibitors of HIV-1 reverse transcriptase. Biochem Biophys Res Commun. 302 (2003) 253-264.
[10] A. Bacchi, M. Carcelli, C. Compari, et al. HIV-1 in strand transfer chelating inhibitors: A focus on metal binding. Mol Pharm. 8 (2011) 507-519.
[11] J. Didierjean, C. Isel, F. Querre, et al. Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones. Antimicrob Agents Chemother. 49 (2005) 4884-4894.
[12] B. S. Van Asbeck, N. A. Georgiou, T. Van der Bruggen, M. Oudshoorn, H. Nottet, J. Marx, Review Anti-HIV effect of iron chelators: different mechanisms involved. J Cinical Virol. 20 (2001) 141-147.
[13] C. Sappey, J. R. Boelaert, S. Legrand-Poels, C. Forceille, A. Favier, J. Piette, Iron chelation decreases NF-κB and HIV type 1 activation due to oxidative stress. AIDS Res Hum Retroviruses. 11 (1995) 1049-1061.
[14] E. C. Moore, M. S. Zedeck, K. C. Agrawal, A. C. Sartorelli, Inhibition of Ribonucleoside Diphosphate Reductase by 1-Formylisoquinoline Thiosemicarbazone and Related Compounds. Biochemistry. 9 (1970) 4492-4498.
[15] S. M. Hecht, RNA Degradation by Bleomycin, a Naturally Occurring Bioconjugate. Bioconjug Chem. 5 (1994) 513-526.
[16] N. Georgiou, T. van der Bruggen, M. Oudshoorn, H. Nottet, J. Marx, S. van Asbeck, Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Mononuclear Blood Cells by the Iron Chelators Deferoxamine, Deferiprone, and Bleomycin. J Infect Dis. 181 (2000) 484-490.
[17] A. R. Karlström, R. L. Levine, Copper inhibits the protease from human immunodeficiecy virus 1 by both cysteine-dependent and cysteine-independent mechanisms. Proc Natl Acad Sci USA. 88 (1991) 5552-5556.
[18] N. V. Loginova, T. V. Koval’chuk, G. I. Polozov, et al. Synthesis, characterization, antifungal and anti-HIV activities of metal(II) complexes of 4,6-di-tert-butyl-3-[(2-hydroxyethyl)thio]benzene-1,2-diol. Eur J Med Chem. 43 (2008) 1536-1542.
[19] S. A. Galal, A. S. Abd El-All, K. H. Hegab, A. A. Magd-El-Din, N. S. Youssef, H. I. El-Diwani, Novel antiviral benzofuran-transition metal complexes. Eur J Med Chem. 45 (2010) 3035-3046.
[20] S. García-Gallego, M. J. Serramía, E. Arnaiz, et al.
Transition-metal complexes based on a sulfonate-containing N-donor ligand and their use as HIV antiviral agents. Eur J Inorg Chem. 10 (2011) 1657-1665.
[21] F. Lebon, N. Boggetto, M. Ledecq, et al. Metal-organic compounds: a new approach for drug discovery. N1-(4-methyl-2-pyridyl)-2,3,6-trimethoxybenzamide copper(II) complex as an inhibitor of human immunodeficiency virus 1 protease. Biochem Pharmacol. 63 (2002) 1863-1873.
[22] G. Pelosi, F. Bisceglie, F. Bignami, et al. Antiretroviral activity of thiosemicarbazone metal complexes. J Med Chem. 53 (2010) 8765-8769.
[23] Q. Wang, Y. T. Wang, S. P. Pu, Y. T. Zheng, Zinc coupling potentiates anti-HIV-1 activity of baicalin. Biochem Biophys Res Commun. 324 (2004) 605-610.
[24] E. De Clercq, Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV)
infection. Med Res Rev., 20 (2000) 323-349.
[25] B. Q. Li, T. Fu, Y. Dongyan, J. A. Mikovits, F. W. Ruscetti, J. M. Wang, Flavonoid baicalin inhibits HIV-1 infection at the level of viral entry. Biochem Biophys Res Commun. 276 (2000) 534-538.
[26] I. Neves, A. L. Bertho, V. G. Veloso, D. V. Nascimento, D. Campos-Mello, M. G. Morgado, Improvement of the lymphoproliferative immune response and apoptosis inhibition upon in vitro treatment with zinc of peripheral blood mononuclear cells (PBMC) from HIV+ individuals. Clin Exp Immunol. 111 (1998) 264-268.
[27] Y. Haraguchi, H. Sakurai, S. Hussain, B. M. Anner, H. Hoshino, Inhibition of HIV-1 infection by zinc group metal compounds. Antiviral Res., 43 (1999) 123-133.
[28] A. Ross, J. Choi, T. M. Hunter, et al. Zinc(II) complexes of constrained antiviral macrocycles. Dalt Trans. 41 (2012) 6408-6418.
[29] E. Wong, R. W. Y. Sun, N. P. Y. Chung, C. L. S. Lin, N. Zhu, C. M. Che, A mixed-valent ruthenium-oxo oxalato cluster Na7[Ru 4(μ3-O)4(C2O4) 6] with potent anti-HIV activities. J Am Chem Soc., 128 (2006) 4938-4939.
[30] J. S. Oxford, M. A. Zuckerman, E. Race, R. Dourmashkin, K. Broadhurst, P. M. Sutton, Sodium deoxycholate exerts a direct destructive effect on HIV and influenza viruses in vitro and inhibits retrovirus-induced pathology in an animal model. Antivir Chem Chemother. 5 (1994) 176-181.
[31] C. J. Elias, L. L. Heise, Challenges for the development of female-controlled vaginal microbicides. AIDS. 8 (1994) 1-9.
[32] A. N. Vzorov, D. Bhattacharyya, L. G. Marzilli, R. W. Compans, Prevention of HIV-1 infection by platinum triazines. Antiviral Res., 65 (2005) 57-67.
[33] N. A. Al-Masoudi, B. A. Saleh, N. A. Karim, A. Y. Issa, C. Pannecouque, Synthesis and Anti-HIV Activity of New 2-Thiolumazine and 2-Thiouracil Metal Complexes. Heteroat Chem. 22 (2011) 44-50.
[34] P. N. Fonteh, F. K. Keter, D. Meyer, New bis(thiosemicarbazonate) gold(III) complexes inhibit HIV replication at cytostatic concentrations: Potential for incorporation into virostatic cocktails. J Inorg Biochem., 105 (2011) 1173-1180.
[35] H. Beraldo, D. Gambino, The Wide Pharmacological Versatility of Semicarbazones, Thiosemicarbazones and Their Metal Complexes. Mini-Reviews Med Chem. 4 (2004) 31-39.
[36] W. Hernándeza, J. Paz, A. Vaisberg, E. Spodine, R. Richter, L. Beyer, Synthesis, characterization, and in vitro cytotoxic activities of benzaldehyde thiosemicarbazone derivatives and their palladium (II) and platinum (II) complexes against various human tumor cell lines. Bioinorg Chem Appl. (2008) 690952.
[37] V. Mishra, S. N. Pandeya, C. Pannecouque, M. Witvrouw, E.
De Clercq, Anti-HIV activity of thiosemicarbazone and semicarbazone derivatives of (±)-3-menthone. Arch Pharm (Weinheim). 335 (2002) 183-186.
[38] S. P. Pricker, Medical uses of gold compounds: Past, present and future. Gold Bull., 29 (1996) 53-60.
[39] P. N. Fonteh, F. K. Keter, D. Meyer, I. A. Guzei, J. Darkwa,
[40] Tetra-chloro-(bis-(3,5-dimethylpyrazolyl)methane)gold(III)
chloride: An HIV-1 reverse transcriptase and protease inhibitor. J Inorg Biochem. 103 (2009) 190-194.
[41] M. Mphahlele, M. Papathanasopoulos, M. A. Cinellu, et al. Modification of HIV-1 reverse transcriptase and integrase activity by gold(III) complexes in direct biochemical assays. Bioorganic Med Chem. 20 (2012) 401-407.
)